Receive a FREE Mesothelioma Treatment
Information Packet


Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma

Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and kill them without harming normal cells. It is not yet known if combination chemotherapy is more effective with or without bevacizumab in treating malignant mesothelioma. Randomized phase II trial to compare the effectiveness of combination chemotherapy with or without bevacizumab in treating patients who have malignant mesothelioma.

Inclusion Criteria:
Histologically or cytologically confirmed malignant pleural or peritoneal mesothelioma that is not amenable to curative surgery.

Location/Contact Information:
City of Hope Comprehensive Cancer Center, Duarte, California, 91010-3000, United States;
Marianna Koczywas, MD 626-359-8111

City of Hope Medical Group, Pasadena, California, 91105, United States; Recruiting
Mark V. McNamara, MD 626-396-2900

University of California Davis Cancer Center, Sacramento, California, 95817, United States;
David R. Gandara, MD 916-734-3772

Decatur Memorial Hospital Cancer Care Institute, Decatur, Illinois, 62526, United States;
James L. Wade, MD 217-876-6603

Ingalls Memorial Hospital, Harvey, Illinois, 60426, United States;
Mark F. Kozloff, MD 708-333-2300

LaGrange Memorial Hospital, LaGrange, Illinois, 60525, United States; Recruiting
James E. Hannigan, MD 708-579-3418

Louis A. Weiss Memorial Hospital, Chicago, Illinois, 60640, United States; Recruiting
Gary D. Steinberg, MD 773-564-5272

Loyola University Medical Center, Maywood, Illinois, 60153, United States; Recruiting
Joseph I. Clark, MD 708-327-3236

Oncology/Hematology Associates of Central Illinois, P.C., Peoria, Illinois, 61602, United States;
James A. Knost, MD, FACP 309-672-5681

University of Chicago Cancer Research Center, Chicago, Illinois, 60637-1470, United States;
Hedy L. Kindler, MD 773-702-0360

CCOP - Northern Indiana CR Consortium, South Bend, Indiana, 46601, United States;
David Allen Taber, MD 800-284-7370

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne, Indiana, 46885-5099, United States;
David Frank Sciortino, MD 219-484-8830

Lakeland Medical Center - St. Joseph, Saint Joseph, Michigan, 49085, United States;
Eric P. Lester, MD 616-982-4963

New York
Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States;
Lee M. Krug, MD 212-639-8420

University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, 19104-4283, United States;
James Stevenson, MD 215-662-8756

University of Texas - MD Anderson Cancer Center, Houston, Texas, 77030-4009, United States;
Charles Lu, MD 713-792-6363

Study chairs or principal investigators
Hedy L. Kindler, MD, Study Chair
University of Chicago Cancer Research Center